Gilead Sciences | GILD - Cost Of Sales


Gilead Sciences reported $1000M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
AbbVie USD 4.29B 73M Jun/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
ALKERMES USD 120.7M 47.44M Jun/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amgen USD 1.87B 271M Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Coherus Biosciences USD 4.04M 324K Dec/2025
Eli Lilly USD 3.27B 309M Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Glaxosmithkline GBP 1.88B 1.6B Mar/2026
Incyte USD 104.96M 457K Jun/2026
J&J USD 8B 67M Jun/2026
Merck USD 3.14B 200M Jun/2026
Moderna USD 93M 862M Jun/2026
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.02B 656M Jun/2026
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
United Therapeutics USD 99.5M 33.9M Jun/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026